Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus
Authors:
- 1 March 2005
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 19 (2) , 273-278
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas–kidney, and pancreas transplantationClinical Transplantation, 2004
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- HLA Points Assigned in Cadaveric Kidney Allocation Should Be Revisited: An Analysis of HLA Class II Molecularly Typed Patients and DonorsAmerican Journal of Transplantation, 2003
- Cytomegalovirus Infection in Solid Organ TransplantationPharmacoEconomics, 2003
- Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1Transplantation, 2002
- A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisNew England Journal of Medicine, 2002
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- SIGNIFICANCE OF CYTOMEGALOVIRUS FOR LONG-TERM SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1998
- INCIDENCE AND PREDICTORS OF CYTOMEGALOVIRUS PNEUMONIA IN ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS1Transplantation, 1996